MAPK3 and acute myeloid leukemia: By using an integrated proteogenomic approach, Cremer et al.41 demonstrated that innate or acquired activation of the RAS/MAPK/ERK1/2 signaling pathway confers resistance to SYK inhibition, indicating that this pathway is a major effector and reciprocal modulator of SYK-dependent signaling in AML.